m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01822)
Name
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
Synonyms
CHEMBL402990; N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)
    Click to Show/Hide
Status
Investigative
Structure
Formula
C13H13NO5
InChI
1S/C13H13NO5/c1-18-10-3-4-11-9(7-10)6-8(13(16)19-11)2-5-12(15)14-17/h3-4,6-7,17H,2,5H2,1H3,(H,14,15)
InChIKey
JUDXBTMVZVWJNP-UHFFFAOYSA-N
PubChem CID
44446277
TTD Drug ID
D08ICI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-2 (MMP-2)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-2 (MMP-2). [2], [3]
Matrix metalloproteinase-9 (MMP-9)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [1], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl). The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) through regulating the expression of Matrix metalloproteinase-9 (MMP-9). [4], [5]
References
Ref 1 CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion. Thorac Cancer. 2019 Jun;10(6):1479-1488. doi: 10.1111/1759-7714.13097. Epub 2019 May 23.
Ref 2 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem. 2008 Mar 13;51(5):1406-14. doi: 10.1021/jm701087n. Epub 2008 Feb 8.
Ref 3 RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2. Melanoma Res. 2019 Aug;29(4):382-389. doi: 10.1097/CMR.0000000000000580.
Ref 4 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. doi: 10.1016/j.bmc.2006.11.017. Epub 2006 Nov 14.
Ref 5 The aberrant cross-talk of epithelium-macrophages via METTL3-regulated extracellular vesicle miR-93 in smoking-induced emphysema. Cell Biol Toxicol. 2022 Feb;38(1):167-183. doi: 10.1007/s10565-021-09585-1. Epub 2021 Mar 4.